Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of aH5N1 (Aflunov) versus Fluad in adults and elderly with and without underlying medical conditions
2011-003603-37Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated) in influenza pandemic (2 arms), sponsored by Novartis. Primary endpoints: Primary immunogenicity endpoint and Primary immunogenicity objective. Started Dec 2013; status: completed.
02
Drugs
Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)
03
Conditions
influenza pandemic
Beyond the preview
Go deeper on 2011-003603-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003603-37.